Evidence map›Paper›PMID 39837296›Full record

ArticleNeuroendocrinology2025

Impact of Indoleamine 2,3-Dioxygenase Enzyme Activity in Neuroendocrine Tumors.

Camilla Mancini, Giulia Pecora, Gerardo Salerno, Luana Lionetto, Donatella De Bernardini, Giuseppe Costanzi, Saverio Gabrielli, Domenico Veroli, Vincenzo Visco, Maurizio Simmaco and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuroendocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Camilla ManciniUnit of Endocrinology, Department of Clinical and Molecular Medicine, Sant'Andrea University Hospital, ENETS Center of Excellence, Sapienza University of Rome, Rome, Italy.
Giulia PecoraUnit of Endocrinology, Department of Clinical and Molecular Medicine, Sant'Andrea University Hospital, ENETS Center of Excellence, Sapienza University of Rome, Rome, Italy.
Gerardo SalernoLaboratory of Clinical Biochemistry, Department of Clinical and Molecular Medicine, Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Italy.
Luana LionettoMass Spectrometry Section, Clinical Biochemistry Laboratory, Sant'Andrea University Hospital, Rome, Italy.
Donatella De BernardiniMass Spectrometry Section, Clinical Biochemistry Laboratory, Sant'Andrea University Hospital, Rome, Italy.
Giuseppe CostanziMass Spectrometry Section, Clinical Biochemistry Laboratory, Sant'Andrea University Hospital, Rome, Italy.
Saverio GabrielliUnit of Endocrinology, Department of Clinical and Molecular Medicine, Sant'Andrea University Hospital, ENETS Center of Excellence, Sapienza University of Rome, Rome, Italy.
Domenico VeroliLaboratory of Clinical Biochemistry, Department of Clinical and Molecular Medicine, Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Italy.
Vincenzo ViscoLaboratory of Clinical Biochemistry, Department of Clinical and Molecular Medicine, Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Italy.
Maurizio SimmacoDepartment of Neuroscience, Mental Health and Sensory Organs, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome, Italy.
Virginia ZamponiUnit of Endocrinology, Department of Clinical and Molecular Medicine, Sant'Andrea University Hospital, ENETS Center of Excellence, Sapienza University of Rome, Rome, Italy.
Rossella MazzilliUnit of Endocrinology, Department of Clinical and Molecular Medicine, Sant'Andrea University Hospital, ENETS Center of Excellence, Sapienza University of Rome, Rome, Italy.
Antongiulio FaggianoUnit of Endocrinology, Department of Clinical and Molecular Medicine, Sant'Andrea University Hospital, ENETS Center of Excellence, Sapienza University of Rome, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIndoleamine 2,3-dioxygenase (IDO) converts L-tryptophan (T) to L-kynurenine (K) resulting in an immunosuppressive microenvironment. The aim of the current study was to evaluate in patients with neuroendocrine tumor (NET) (1) T and K concentrations; (2) correlation with clinical outcome; (3) relationship between IDO activity and inflammatory cytokines.

methodsA cross-sectional study was performed to investigate the IDO pathway in patients in follow-up for NET. Clinicopathological features, serum levels of K and T through liquid chromatography, and serum assay of cytokines (IL-6, IL-10, IL-17A, IL-22, IL-23, TNF-α) through MAGPIX were evaluated.

resultsSeventy-eight NET patients were enrolled (66 lung, 12 pancreatic): 69.2% were in postoperative remission, 14.1% in stable disease, and 16.7% in disease progression. T was significantly lower in patients older than 65 years (p = 0.003). K and T were significantly lower in patients with progression (p = 0.03, p = 0.004, respectively). T was an independent predictor factor of progression in multivariable analysis (p = 0.041). A cutoff of 7.74 μg/mL significantly differentiates patients with progression and those with stable disease. IL-6 and IL-10 were significantly associated with tumor progression in univariate analysis (p = 0.005, p = 0.001, respectively) but not in the multivariable analysis. A statistically significant negative correlation was found between T and IL-10 (r = -0.366, p value = 0.04).

conclusionThe K/T pathway may play a role as a potential predictor of tumor progression in NET. These findings need to be validated in large prospective studies investigating its metabolites as both prognostic and predictive factors for treatment response.

Indexed as

Indoleamine-Pyrrole 2,3,-DioxygenaseKynurenineLung NeoplasmsNeuroendocrine TumorsPancreatic NeoplasmsAdultAgedCross-Sectional StudiesCytokinesDisease ProgressionFemaleHumansMaleMiddle AgedTryptophanCytokinesIndoleamine-Pyrrole 2,3,-DioxygenaseKynurenineTryptophanCytokinesImmunotherapyIndoleamine 2,3-dioxygenaseKynurenineNeuroendocrine tumorsTryptophan

Identifiers

PMID39837296
PMCPMC12169804

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.